Medifast, the parent company for OPTAVIA, announced its financial results for the third quarter of 2025. Revenue during the quarter fell 36.2% to $89.4 million, which the company attributed to a decrease in the number of active earning OPTAVIA coaches. Total active earning OPTAVIA coaches declined 35% from 30,000 in Q3 2024 to 19,500 in the third quarter of 2025. This decline in the number of coaches is a trend that began in the first quarter of 2023, driven by “continued challenges with client acquisition due to the growing acceptance of GLP-1 medications for weight loss.”
The company reported a net loss of $2.3 million and a 41.2% decrease in gross profit, from $105.7 million in Q3 2024 to $62.2 million. Lower revenue was the primary driver for this shift, partially offset by lower cost of sales.
Loss from operations during the quarter was $4.1 million, compared to income from operations of $2.1 million in the same period last year. “Other income” grew approximately $2 million to $1.4 million as compared to “other expenses” of $0.5 million in Q3 2024. This improvement was primarily due to the absence of a loss on the company’s investment in LifeMD, Inc. common stock in 2024.
“We’re transforming Medifast from a weight-loss company into a leader in promoting metabolic health,” said Dan Chard, Medifast Chairman and Chief Executive Officer. “Our clinically proven, coach-guided system does more than help people lose weight—it addresses the underlying metabolic dysfunction that drives most health challenges. This strategic evolution positions us in a larger, more durable market with strong consumer tailwinds. It’s a transformation founded in proven science that creates meaningful health outcomes. With a strong balance sheet, a passionate coach community, and clinically proven plans, we believe Medifast is well positioned to become the trusted partner for millions seeking metabolic health.”
The company ended the quarter with $173.5 million in cash, cash equivalents and investment securities with no debt. This is up from $162.3 million at the end of 2024. Fourth quarter 2025 revenue is now expected in the range of $65 million to $80 million and Q4 2025 diluted loss per share is anticipated to be in the range of $0.70 to $1.25.
The post Medifast Reports Q3 2025 Financial Results first appeared on Direct Selling News.
